Making a difference 2020-2021

TICK SALIVA PROTEIN COULD ONE DAY HELP TREAT INFLAMMATORY DISEASES A team of researchers at the ARC Centre of Excellence for Innovations in Peptide and Protein Science (CIPPS) has for the first time synthetically produced anti-inflammatory proteins found in tick saliva, a promising step towards new therapeutic treatments. Evasins, as the proteins are known, act in human blood to suppress a class of transmitter proteins, which is whywhen bitten, we often don’t notice a tick has burrowed into our skin. Scientists nowwant to see howthese proteins can be used for treating human diseases, including potential application for lung inflammation in respiratory illness, such as COVID-19. ‘Ticks have a terrible reputation – they are not very nice to look at, need to suck blood to survive and are responsible for transmitting bacteria that cause severe diseases, such as Lyme disease in humans,’ said Professor Richard Payne, an ARC Future Fellow and Deputy Director at CIPPS, who is based at The University of Sydney. ‘But to a medicinal chemist, ticks are amazing creatures.’ Ticks have evolved an impressive arsenal of biologically active salivary proteins they pump into the bite sites on their hosts. Among these are various pain-killing agents and some of the best blood-thinning molecules known. ‘In order to avoid detection, ticks also produce small protein molecules that suppress the inflammatory response. These proteins are called the 'evasins' because they help the tick evade immune detection. This means they can feed for days without the host knowing they are attached,’ Professor Payne says. In the past, evasins have proven difficult to isolate, so the researchers, led by CIPPS Research FellowDr Charlotte Franck, built the proteins from scratch in a feat of synthetic chemistry, something that no one else had ever

been able to do. They discovered that sulfate molecules attached to evasins give the proteins a powerful kick. ‘Armedwith this knowledge, evasins could potentially be repurposed to suppress chemokine-driven inflammation in human disease,’ Dr Franck says. ‘We are nowtrying to engineer these sulfated evasin molecules to make themmore stable in blood. We can then start to explore how effective they could be for a range of inflammatory conditions in the clinic.’ The findings were part of Dr Franck’s doctoral research andwas funded by an ARC Discovery Project and NHMRC Project Grant. The CIPPS teamwill continue to build on this knowledge to try to make the sulfated evasins more effective.

(Above) Dr Charlotte Franck at the School of Chemistry. Credit: The University of Sydney. (Right) Credit:



Made with FlippingBook Converter PDF to HTML5